In this Issue:
Novel mAbs prolong HBV suppression in mice
HCC risk score in Caucasian patients with CHB
Lactic acidosis with ribavirin+sofosbuvir in HCV cirrhosis
Antisense oligonucleotide therapy for CHB?
APRI & FIB-4 scores do not stage hepatic fibrosis in CHB
HEV infection is endemic in France
mAb AP33 prevents HCV infection in humanised mice
Ledipasvir+sofosbuvir ± ribavirin treats GT1 HCV in the elderly
STAT4 rs7574865 predicts response to IFNα therapy in CHB
Strategies to reduce HCV in PWID populations
Please login below to download this issue (PDF)